Investment case
iBio, Inc.
IBIO · 3 developments mapped · last assessed 2026-08-28
Market Ontology has mapped 3 macro, policy, and market developments to iBio, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for IBIO yet, so no modelled value is shown. The IBIO valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IBIO on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
iBio, Inc. ATM — $100M
Direct equity dilution and potential downward pressure on share price due to increased supply.
· Moves shares outstanding, cost of equity (due to increased risk perception or liquidity impact)
- Open question
iBio, Inc. Follow-On — $100M
Direct equity dilution and capital infusion for operations. The 'Open Market Sale Agreement' suggests a controlled, 'at-the-market' offering, which can spread dilution over time but still introduces selling pressure.
· Moves future share count for eps calculations, discount rate (wacc) due to potential change in capital structure and risk perception, probability of success for clinical programs (if funding enables progress)
What changed, by assumption
- 2026-08-28iBio, Inc. ATM — $100M
- 2026-08-28iBio, Inc. Follow-On — $100M
- 2026-08-27Interpace Biosciences Announces 1-for-5 Reverse Stock Split for Nasdaq Uplisting
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-28 | Capital expenditure | Bullish | Increased spending on R&D and CMC activities for clinical-stage programs IBIO-600 and IBIO-610. | 0.80 |
| 2026-08-28 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-28 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-28 | iBio, Inc. ATM — $100M | Bearish | 1-3m | 0.80 |
| 2026-08-28 | iBio, Inc. Follow-On — $100M | mixed | 1-3m | 0.80 |
| 2026-08-27 | Interpace Biosciences Announces 1-for-5 Reverse Stock Split for Nasdaq Uplisting | mixed | 1-3m | 0.70 |